HT-KIT receives FDA Orphan Drug Designation for SM
HT-KIT, a precision antisense oligonucleotide (ASO) therapy targeting KIT-driven malignancies and SM, has shown promising results in trials.
HT-KIT, a precision antisense oligonucleotide (ASO) therapy targeting KIT-driven malignancies and SM, has shown promising results in trials.
A rare case of SM associated with a skin lymphoma was recently reported, and is the only known case of the lymphoma occurring with BMM.
Eosinophil, monocyte and leukocyte counts could correlate with the severity of systemic mastocytosis (SM) and predict outcomes.
A recent case report describes the specially tailored anesthetic protocol for a C-section in a woman with systemic mastocytosis (SM).
Aggressive systemic mastocytosis (SM) can present with nonspecific symptoms like fever, which can complicate diagnosis
A new cumulative analysis from the PIONEER trial provides encouraging long-term data on avapritinib for indolent SM.
A case report was recently published describing a man with systemic mastocytosis and a previously unknown KIT mutation.
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) appears to have a higher mutational burden than isolated SM.
A rare presentation of systemic mastocytosis (SM) alongside postural orthostatic tachycardia syndrome (POTS) was recently reported.
Well-differentiated systemic mastocytosis (WDSM), a rare SM variant, was recently associated with previously unknown genetic mutations.